Document is current
Any future updates will be listed below
-
Authors
Bai, Zhiliang https://orcid.org/0000-0002-3977-3057
Feng, Bing https://orcid.org/0000-0002-6108-2017
McClory, Susan E.
de Oliveira, Beatriz Coutinho
Diorio, Caroline
Gregoire, Céline
Tao, Bo https://orcid.org/0000-0002-5490-4668
Yang, Luojia
Zhao, Ziran
Peng, Lei
Sferruzza, Giacomo
Zhou, Liqun
Zhou, Xiaolei
Kerr, Jessica
Baysoy, Alev
Su, Graham
Yang, Mingyu
Camara, Pablo G.
Chen, Sidi https://orcid.org/0000-0002-3819-5005
Tang, Li https://orcid.org/0000-0002-6393-982X
June, Carl H. https://orcid.org/0000-0003-0241-3557
Melenhorst, J. Joseph https://orcid.org/0000-0001-7677-537X
Grupp, Stephan A. https://orcid.org/0000-0001-8030-7595
Fan, Rong https://orcid.org/0000-0001-7805-8059
- License Information
-
More Information
Article History
Received: 28 May 2023
Accepted: 27 June 2024
First Online: 25 September 2024
Competing interests
: R.F. is scientific founder and adviser for IsoPlexis, Singleron Biotechnologies and AtlasXomics. The interests of R.F. were reviewed and managed by Yale University Provost’s Office in accordance with the University’s conflict of interest policies. S.A.G. reports grants, personal fees and other support from Novartis and Vertex; grants from Jazz, Kite and Servier; personal fees and/or scientific advisory boards from Roche, GSK, CBMG, Janssen/J&J, Jazz, Adaptimmune, TCR2, Cellectis, Juno, Allogene and Cabaletta; in addition, S.A.G. has a patent for Toxicity management for antitumour activity of CARs, WO 2014011984 A1 issued. J.J.M. and C.H.J. hold patents related to CAR T cell manufacturing and biomarker discovery. C.H.J. is a scientific founder of Tmunity Therapeutics and DeCART Therapeutics, and is a member of the scientific advisory boards of AC Immune, BluesphereBio, Cabaletta, Carisma, Cartog-raphy, Cellares, Celldex, Decheng, Poseida, Verismo, WIRB-Copernicus and Ziopharm. L.T. is a co-founder, share-holder and advisor for Leman Biotech. The interests of L.T. were reviewed and managed by EPFL. S.C. is a co-founder of EvolveImmune, Cellinfinity, NumericGlobal and Chen Consulting, all unrelated to this study. The other authors declare no other competing interests.
